Aeglea BioTherapeutics, Inc.

The momentum for this stock is not very good. Aeglea BioTherapeutics, Inc. is not a good value stock. Aeglea BioTherapeutics, Inc. is not very popular among insiders. Aeglea BioTherapeutics, Inc. is a mediocre stock to choose.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in th...

News

Aeglea BioTherapeutics Announces Grants of Inducement Awards

PR Newswire Aeglea BioTherapeutics Announces Grants of Inducement Awards Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Nov. 3, 2023 WALTHAM, Mass., Nov. 3, 2023...\n more…

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE)

PR Newswire SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation...\n more…

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

PR Newswire Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences PR Newswire WALTHAM, Mass., Oct. 30...\n more…

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

Aeglea BioTherapeutics (NASDAQ:AGLE) Downgraded by StockNews.com to "Sell"

Ticker Report StockNews.com cut shares of Aeglea BioTherapeutics (NASDAQ:AGLE Free Report) from a hold rating to a sell rating in a research report released on Tuesday morning. Several other research...\n more…

Aeglea BioTherapeutics (NASDAQ:AGLE) Research Coverage Started at StockNews.com

Zolmax Research analysts at StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Free Report) in a report issued on Thursday. The firm set a hold rating...\n more…